A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Clinical trial NCT06079879 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06079879
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-31
- Primary completion
- 2027-07-30
- Enrollment
- 340
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.